Cancer Stem Cells Drug Discovery Platform
Please click here to refer to our Corporate Presentation for additional details.
TriStar is the first company able to offer in-vitro as well as in-vivo
assays for the screening of small molecule compounds and therapeutic
antibodies on Cancer Stem Cells (CSCs) of Breast, Colon, Lung (NSCL &
SCLC), Glioblastoma, Melanoma, Ovarian & Thyroid Cancers. The
availability of these assays may provide a unique opportunity for
pharmaceutical companies to access state of the art technology in
cancer research on the largest commercially available set of cancer
stem cells.
Cancer Stem Cells (CSCs) are the sub-population of undifferentiated tumorigenic cells responsible for the initiation, maintenance and spreading of tumors and should, therefore, represent the preferential target of effective therapies aimed at eradicating tumors. CSCs represent a powerful tool for basic and translational researchers aimed at studying the pathogenic events that drive cancer initiation and progression, while providing crucial information for the development of therapeutic compounds targeting specific survival pathways of the tumorigenic population. The analysis of basic biological parameters concerning CSCs may provide important information to determine their prognostic value in a clinical setting.
TriStar offers the following unique screening platforms using Cancer Stem Cells:
- Cytoinclusion Arrays (formalin fixed) to simultaneously screen 50 donor samples of various CSCs for markers of interest.
- Characterization of CSCs by immunoblot, confocal microscopy, flow cytometry & real-time PCR
- In-vitro testing of small molecule compounds & antibodies
- In-vivo testing using CSC derived tumor xenografts (subcutaneous or orthotopic)
New Arrays Click here for product lists
- Normal Tissue Array 96
- Multi Tumor Tissue Array 880
- Human Cancer Stem Cell (CSC) cytoinclusion array with matched CSC generated xenografts
- Breast cancers primary & paired distant metastases
- Triple negative breast cancer with follow up information
- Breast cancers with trastuzumab treatment data
- Breast cancer prognosis array 600
- Colon cancer progression array
- Colon cancer Stage II-III with KRAS data
- Colon cancer Stage IV with KRAS data
- Colon cancer with bevacizumab treatment information
- Colon cancer prognosis array
- Prostate cancer heterogeneity array
- Prostate cancer progression array 370
- Hormone refractory prostate cancers
- Prostate cancer prognosis array
- Small cell lung cancer (SCLC)
- Lung cancer prognosis array 400 with treatment information
- Pancreatic cancer primary & matched mets
- Multiple Myeloma 60
- Non-Hodgkin's Lymphoma High Grade 152
- Non-Hodgkin's Lymphoma Low Grade 71
32 normal human tissues, 3 donors each
50 donor samples each of lung adenocarcinoma,
lung squamous,lung undifferentiated,SCLC, breast lobular,
breast ductal, prostate, colon, NHL, head & neck, pancreatic, esophageal adenocarcinoma, esophageal squamous, bladder, kidney, melanoma mets, liver, ovarian
Cytospins of multiple human cancer stem cell lines of breast, colon, lung, glioblastoma & melanoma Xenografts generated from the same lines of breast, colon, lung & melanoma
35 primary tumors, 35 paired distant mets
Triple negative breast cancer with follow up information including treatment & response
40 breast cancers with follow up data including trastuzumab responders & non-responders
600 breast cancers with follow-up information
50 low grade adenoma, 50 high grade adenoma, 50 pT2, 50 pT3, 50 nodal mets, 50 liver mets, 10 normals
40 CRC with KRAS data, including mutations & wild type
40 CRC with KRAS data, including mutations & wild type
23 CRC with follow up information including bevacizumab treatment (metastatic & adjuvant) & response, 4 normals
300 colon cancers with follow-up information, with KRAS data incl mutations, treatment information
50 donors, one core each from 8 different primary tumor blocks per donor
Prostate cancer progression array 370 donors
50 HR prostate cancers
500 prostate cancers with 10 yr follow up information
30 donor samples SCLC
400 NSCLC with follow up information
30 pancreatic cancers with paired PT mets
60 multiple myeloma specimens
162 specimens of high grade NHL
69 specimens of low grade NHL